69 Biggest Movers From Friday
Gainers
Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 69 companies set new 52-week lows.
Invitae Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q1, Invitae (NYSE:NVTA) posted sales of $123.69 million. Earnings were up 11.34%, but Invitae still reported an overall loss of $181.86 million.
Analyst Ratings for Invitae
Analysts have provided the following ratings for Invitae (NYSE:NVTA) within the last quarter:
Morgan Stanley Maintains Equal-Weight on Invitae, Lowers Price Target to $17
Morgan Stanley analyst Tejas Savant maintains Invitae (NYSE:NVTA) with a Equal-Weight and lowers the price target from $18 to $17.
Recap: Invitae Q1 Earnings
Invitae (NYSE:NVTA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
Invitae missed estimated earnings by 2.63%, reporting an EPS of $-0.78 versus an estimate of $-0.76.
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
